U.S. market Closed. Opens in 4 hours 2 minutes

AGRX | Agile Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.4400 - 1.5100
52 Week Range 0.2000 - 2.6300
Beta 1.54
Implied Volatility 297.16%
IV Rank 32.67%
Day's Volume 119,291
Average Volume 143,293
Shares Outstanding 6,904,500
Market Cap 10,425,795
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2014-05-23
Valuation
Profitability
Growth
Health
P/E Ratio -0.89
Forward P/E Ratio N/A
EPS -1.70
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 19
Country USA
Website AGRX
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.
AGRX's peers: AMRX, AQST, ASRT, AVDL, BFRI, CPIX, CYTH, DRRX, ZOM, ESPR, EVOK, KMDA, PTPI, RDHL, RMTI, TXMD, SHPH
*Chart delayed
Analyzing fundamentals for AGRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AGRX Fundamentals page.

Watching at AGRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AGRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙